Simulations Plus, Inc. has recently released its 10-Q report, providing an insight into the company's financial performance. Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning-based technology worldwide. The company operates through Software and Services segments and offers a range of products and consulting services to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies.
In the report, Simulations Plus, Inc. reported total revenues of $18.924 million for the three months ended November 30, 2024, compared to $14.5 million for the same period in 2023. The company's gross profit for the same period was $10.218 million, compared to $9.848 million in 2023. Simulations Plus, Inc. also reported income from operations of $126,000, a decrease from $960,000 in the previous year. The net income for the three months ended November 30, 2024, was $206,000, compared to $1.945 million for the same period in 2023.
The company's total assets as of November 30, 2024, were $196.916 million, compared to $196.639 million as of August 31, 2024. Simulations Plus, Inc. reported total current assets of $40.399 million, with cash and cash equivalents amounting to $6.187 million. The company's long-term assets included intellectual property, goodwill, and other intangible assets, totaling $154.615 million.
Simulations Plus, Inc. also provided a breakdown of its shareholders' equity, which amounted to $184.695 million as of November 30, 2024. The company's common stock and additional paid-in capital balance at the end of the period was $154.424 million, and the retained earnings were $30.560 million.
Furthermore, the report included details of the company's cash flows from operating, investing, and financing activities. Simulations Plus, Inc. reported a net decrease in cash and cash equivalents of $4.124 million for the three months ended November 30, 2024. The company's cash and cash equivalents at the end of the period were $6.187 million, compared to $10.311 million at the beginning of the period.
Today the company's shares have moved -9.9% to a price of $27.37. If you want to know more, read the company's complete 10-Q report here.
